ArticleClinical parkinsonism & related disorders2026
Identification of responsive motor symptom assessment items reflecting plasma levodopa changes in individuals with Parkinson's disease.
Article in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms, including tremors, rigidity, and bradykinesia. Although levodopa remains the gold standard treatment, clinical practice highly depends on subjective patient reporting to assess medication effectiveness, which can be unreliable owing to cognitive decline and motivational factors. We aimed to identify motor symptom assessment variables within the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) framework that reliably reflect plasma levodopa concentration changes in individuals with PD. Methods: Forty-seven participants with PD underwent standardized levodopa challenge testing with concurrent plasma concentration monitoring. Motor symptoms were evaluated using a simplified assessment protocol based on selected MDS-UPDRS variables. Results: Subgroup analysis by baseline tremor status revealed that rigidity demonstrated the most consistent responsiveness across all patient groups, showing large effect sizes (ES) regardless of baseline characteristics (overall ES: 0.65, 57.4% improvement; baseline tremor-absent ES: 0.66, 56.8% improvement; baseline tremor-present ES: 0.62, 60.0% improvement), whereas tremor and bradykinesia effectiveness varied considerably by subgroup. Conclusion: Rigidity assessment within the MDS-UPDRS framework may serve as a robust clinical indicator for monitoring dopaminergic responsiveness, and thereby provide a practical tool to complement subjective patient reporting to enable individualized PD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.